559 related articles for article (PubMed ID: 24012496)
1. Silibinin inhibits β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness.
Wu K; Ning Z; Zeng J; Fan J; Zhou J; Zhang T; Zhang L; Chen Y; Gao Y; Wang B; Guo P; Li L; Wang X; He D
Cell Signal; 2013 Dec; 25(12):2625-33. PubMed ID: 24012496
[TBL] [Abstract][Full Text] [Related]
2. PI3K/Akt to GSK3β/β-catenin signaling cascade coordinates cell colonization for bladder cancer bone metastasis through regulating ZEB1 transcription.
Wu K; Fan J; Zhang L; Ning Z; Zeng J; Zhou J; Li L; Chen Y; Zhang T; Wang X; Hsieh JT; He D
Cell Signal; 2012 Dec; 24(12):2273-82. PubMed ID: 22906492
[TBL] [Abstract][Full Text] [Related]
3. Emodin inhibits epithelial to mesenchymal transition in epithelial ovarian cancer cells by regulation of GSK-3β/β-catenin/ZEB1 signaling pathway.
Hu C; Dong T; Li R; Lu J; Wei X; Liu P
Oncol Rep; 2016 Apr; 35(4):2027-34. PubMed ID: 26820690
[TBL] [Abstract][Full Text] [Related]
4. Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells.
Shan Y; Zhang L; Bao Y; Li B; He C; Gao M; Feng X; Xu W; Zhang X; Wang S
J Nutr Biochem; 2013 Jun; 24(6):1062-9. PubMed ID: 23159064
[TBL] [Abstract][Full Text] [Related]
5. Epithelial-mesenchymal transition transcription factor ZEB1/ZEB2 co-expression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer.
Chu PY; Hu FW; Yu CC; Tsai LL; Yu CH; Wu BC; Chen YW; Huang PI; Lo WL
Oral Oncol; 2013 Jan; 49(1):34-41. PubMed ID: 22892238
[TBL] [Abstract][Full Text] [Related]
6. Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors.
Wu K; Zeng J; Li L; Fan J; Zhang D; Xue Y; Zhu G; Yang L; Wang X; He D
Oncol Rep; 2010 Jun; 23(6):1545-52. PubMed ID: 20428808
[TBL] [Abstract][Full Text] [Related]
7. Fibulin-3-mediated inhibition of epithelial-to-mesenchymal transition and self-renewal of ALDH+ lung cancer stem cells through IGF1R signaling.
Kim IG; Kim SY; Choi SI; Lee JH; Kim KC; Cho EW
Oncogene; 2014 Jul; 33(30):3908-17. PubMed ID: 24013232
[TBL] [Abstract][Full Text] [Related]
8. EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition.
Sato F; Kubota Y; Natsuizaka M; Maehara O; Hatanaka Y; Marukawa K; Terashita K; Suda G; Ohnishi S; Shimizu Y; Komatsu Y; Ohashi S; Kagawa S; Kinugasa H; Whelan KA; Nakagawa H; Sakamoto N
Cancer Biol Ther; 2015; 16(6):933-40. PubMed ID: 25897987
[TBL] [Abstract][Full Text] [Related]
9. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling.
Chen Y; Chen ZY; Chen L; Zhang JY; Fu LY; Tao L; Zhang Y; Hu XX; Shen XC
Biochem Pharmacol; 2019 Aug; 166():33-45. PubMed ID: 31071331
[TBL] [Abstract][Full Text] [Related]
10. BENC-511, a novel PI3K inhibitor, suppresses metastasis of non-small cell lung cancer cells by modulating β-catenin/ZEB1 regulatory loop.
Zhang Q; Zhou L; Guan Y; Cheng Y; Han X
Chem Biol Interact; 2018 Oct; 294():18-27. PubMed ID: 30125547
[TBL] [Abstract][Full Text] [Related]
11. Sonic hedgehog (Shh) signaling promotes tumorigenicity and stemness via activation of epithelial-to-mesenchymal transition (EMT) in bladder cancer.
Islam SS; Mokhtari RB; Noman AS; Uddin M; Rahman MZ; Azadi MA; Zlotta A; van der Kwast T; Yeger H; Farhat WA
Mol Carcinog; 2016 May; 55(5):537-51. PubMed ID: 25728352
[TBL] [Abstract][Full Text] [Related]
12. 3,5,4'-Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
Tsai JH; Hsu LS; Lin CL; Hong HM; Pan MH; Way TD; Chen WJ
Toxicol Appl Pharmacol; 2013 Nov; 272(3):746-56. PubMed ID: 23921149
[TBL] [Abstract][Full Text] [Related]
13. A novel role of ribonuclease inhibitor in regulation of epithelial-to-mesenchymal transition and ILK signaling pathway in bladder cancer cells.
Yao X; Li D; Xiong DM; Li L; Jiang R; Chen JX
Cell Tissue Res; 2013 Sep; 353(3):409-23. PubMed ID: 23703635
[TBL] [Abstract][Full Text] [Related]
14. Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells.
Cufí S; Bonavia R; Vazquez-Martin A; Corominas-Faja B; Oliveras-Ferraros C; Cuyàs E; Martin-Castillo B; Barrajón-Catalán E; Visa J; Segura-Carretero A; Bosch-Barrera J; Joven J; Micol V; Menendez JA
Food Chem Toxicol; 2013 Oct; 60():360-8. PubMed ID: 23916468
[TBL] [Abstract][Full Text] [Related]
15. The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC.
Wang LH; Xu M; Fu LQ; Chen XY; Yang F
Sci Rep; 2018 Aug; 8(1):12776. PubMed ID: 30143678
[TBL] [Abstract][Full Text] [Related]
16. Fas signaling induces stemness properties in colorectal cancer by regulation of Bmi1.
Chen J; Wang Y; Zhuo L; Liu Z; Liu T; Li W; Cai Y; Zheng H
Mol Carcinog; 2017 Oct; 56(10):2267-2278. PubMed ID: 28543447
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of DAPK1 promotes the stemness of cancer stem cells and EMT process by activating ZEB1 in colorectal cancer.
Yuan W; Ji J; Shu Y; Chen J; Liu S; Wu L; Zhou Z; Liu Z; Tang Q; Zhang X; Shu X
J Mol Med (Berl); 2019 Jan; 97(1):89-102. PubMed ID: 30460377
[TBL] [Abstract][Full Text] [Related]
18. Effect of down-regulated transcriptional repressor ZEB1 on the epithelial-mesenchymal transition of ovarian cancer cells.
Chen D; Wang J; Zhang Y; Chen J; Yang C; Cao W; Zhang H; Liu Y; Dou J
Int J Gynecol Cancer; 2013 Oct; 23(8):1357-66. PubMed ID: 24257549
[TBL] [Abstract][Full Text] [Related]
19. Baicalein suppresses metastasis of breast cancer cells by inhibiting EMT via downregulation of SATB1 and Wnt/β-catenin pathway.
Ma X; Yan W; Dai Z; Gao X; Ma Y; Xu Q; Jiang J; Zhang S
Drug Des Devel Ther; 2016; 10():1419-41. PubMed ID: 27143851
[TBL] [Abstract][Full Text] [Related]
20. ZnAs@SiO
Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
[No Abstract] [Full Text] [Related]
[Next] [New Search]
